ArticleFrontiers in public health2025
2021 global burden of disease study: a comprehensive analysis of glaucoma in the middle-aged and older adult population at global, regional, and national levels.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Joint trajectories of obesity and depressive symptoms and risk of incident glaucoma: a 16-year prospective cohort study from the Health and Retirement Study.Frontiers in aging neuroscience · 2026Article
- Clinical Debates in Minimally Invasive Glaucoma Surgeries (MIGSs).Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glaucoma is a leading cause of irreversible blindness globally, with a particularly significant impact on middle-aged and older adults (aged 45 years and above), substantially affecting their quality of life and imposing considerable socio-economic burdens. Comprehensive assessments of the burden of glaucoma in this age group at global, regional, and national levels are crucial for shaping health policies and optimizing resource allocation. Methods: Data on the burden of glaucoma among individuals aged 45 years and above were obtained from the 2021 Global Burden of Disease (GBD) study. The Average Annual Percent Change (AAPC) was used to evaluate trends in glaucoma burden from 1990 to 2021 among this population. The Slope Index of Inequality (SII) and the Concentration Index (CI) were employed to analyze both absolute and relative health inequalities in the burden of glaucoma. An Age-Period-Cohort model focusing on the 45+ age group was fitted using the NORDPRED package to predict the future burden of glaucoma. Additionally, frontier analysis was conducted to assess the relationship between the burden of glaucoma and socio-demographic development in the older adult population, using non-parametric Data Envelopment Analysis (DEA) to define a boundary based on the level of development for the minimal achievable burden. Results: In 2021, there were 5.34 million cases of glaucoma among the global population aged 45 years and above (95% UI: 4.22-6.45 million), with an age-standardized prevalence rate (ASPR) of 889.3 per 100,000 population (95% UI: 700.2-1078.5). The AAPC for glaucoma in this age group from 1990 to 2021 was -0.82 (95% CI: -0.85 to -0.8), indicating a downward trend in both ASPR and age-standardized DALY rate (ASDR) globally among middle-aged and older adults. At the regional level, areas with lower Socio-Demographic Index (SDI) exhibited higher ASPRs, whereas high SDI regions recorded lower rates. Nationally, countries such as Niger and Nigeria demonstrated the highest age-standardized rates within this demographic. Health inequality analyses revealed that countries with lower SDI bear a disproportionately higher burden of glaucoma among middle-aged and older adults. Predictions indicate that although the number of global cases in this age group may rise, the overall burden of glaucoma is expected to gradually decline. Conclusion: As one of the leading causes of blindness among middle-aged and older adults worldwide, glaucoma remains a significant public health concern. Although the absolute number of cases in individuals aged 45 years and above continues to rise due to population growth and aging, both the ASPR and ASDR have shown declining trends. This decline reflects meaningful progress in the prevention, diagnosis, and management of the disease. To address the ongoing increase in case numbers, targeted policy interventions are needed to ensure effective prevention and management strategies, contributing to the achievement of global sustainable development goals. Furthermore, frontier analysis identifying disparities between national development levels and the burden of glaucoma in the older adult population can aid in optimizing the allocation of global health resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.